Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ovarian cancer endpoints workshop

Executive Summary

FDA and the American Society for Clinical Oncology, in conjunction with FDA's Oncologic Drugs Advisory Committee, will hold a public workshop on ovarian cancer endpoints April 26 at the Marriott Hotel in North Bethesda, Md. FDA plans to issue a guidance document from the workshop findings. The agency has previously held meetings on lung, colorectal, prostate and brain cancer endpoints (1"The Pink Sheet" Feb. 6, 2006, p. 15). [Editor's note: To 2watch a webcastor order a video/DVD of this or any other meeting, visit]...

You may also be interested in...

Progression-Free Survival Is Meaningful Endpoint For Glioma Trials

Progression free survival assessed at six months should be considered as a meaningful surrogate endpoint in evaluating primary brain tumor clinical trials for accelerated approval, a panel assembled by FDA agreed

FDA To Ramp Up ASCA Pilot In 2021

A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.

Scotland's MGB Plots Phase III For Promising Antibacterial

With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts